As soon as disease-modifying drugs for the treatment of Parkinson’s disease will be available, it will be important to detect Parkinson’s disease also in these early stages, when the loss of (unilateral) putaminal DAT is considerably below the 50% threshold for motor symptoms. The gene discussed is SLC6A3; the disease is Parkinson disease.